Clinical trials: Primary
Triage
Triaging and Referring in Adjacent General and Emergency Departments
Introduction: Patients who might also go to the general practitioner (GP) frequently consult emergency departments (ED). This leads to additional costs for both government and patient and a high workload for emergency physicians…
- Trial name
- TRIAGE (NCT03793972)
- Testing
- Triage with referral to primary care, Usual care
- Where
- 2 sites in Belgium
- Volunteers
- 8,158 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Restless Legs Syndrome
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS).
- Trial name
- CONCORD (NCT01668667)
- Testing
- GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg
- Where
- 42 sites in United States
- Volunteers
- 501 people
- Sponsor
- XenoPort, Inc.
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Migraine
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in…
- Trial name
- NCT05477095
- Testing
- UB-313
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Axxium Life, Inc.
Migraine
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
The primary purpose of this study is to determine whether erenumab is safe and well tolerated in healthy adults and migraine patients.
- Trial name
- NCT01688739
- Testing
- Erenumab
- Where
- Belgium
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Amgen
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of irofulven in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00053365
- Testing
- irofulven
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Hypertension, Pure Autonomic Failure
Nitric Oxide and the Autonomic Nervous System
The amount of blood flowing to the different parts of the body is regulated by the autonomic (automatic) nerves and by local factors produced by the blood vessels.
- Trial name
- NCT00178919
- Testing
- L-NMMA, Trimethaphan
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Dementia, Memory Disorders
Identifying Patients With Dementia in Primary Care
Veterans who completed GEMS-Phase 1 will be asked to participate in GEMS-Phase 2 to determine the accuracy of methods used to assess mild memory problems.
- Trial name
- GEMS (NCT00289471)
- Testing
- No intervention delivered.
- Where
- United States
- Volunteers
- 630 people
- Sponsor
- US Department of Veterans Affairs
Hereditary Angioedema
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.
- Trial name
- NCT04208412
- Testing
- KVD900
- Where
- 25 sites in United States, Austria and 8 more
- Volunteers
- 84 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Brain Tumor, Primary
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
This is a pilot study to assess the changes in white matter, in the brain, in response to radiation therapy and correlate these changes with later declines in cognitive function.
- Trial name
- NCT02006407
- Testing
- Cranial Radiotherapy, MRI with Diffusion Tensor Imaging (DTI), Neuro-cognitive Testing (CogState)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan Rogel Cancer Center
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
Knee Disease, Arthritis Knee
Intraosseous Morphine in Primary TKA
The research team wants to investigate if an intraosseous injection (directly into the bone marrow) of morphine during primary total knee replacement helps with post-operative pain following primary total knee replacement…
- Conditions
- Knee Disease, Arthritis Knee, Pain, Acute
- Trial name
- NCT04388111
- Testing
- Morphine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The Methodist Hospital Research Institute
Anxiety
Clinical and Cost Effectiveness of Alpha-Stim AID CES
This is a single-centre research study in patients seen within an NHS Improving Access to Psychological Interventions (IAPT) service with suspected generalised anxiety disorder (GAD).
- Trial name
- NCT02901080
- Testing
- Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire
- Where
- United Kingdom
- Volunteers
- 161 people
- Sponsor
- Electromedical Products International, Inc.
Meningococcal Infection (Healthy Volunteers)
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Primary Objective: To demonstrate sufficiency of the vaccine seroresponse to meningococcal serogroups A, C, W, and Y following administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135)…
- Trial name
- NCT04142242
- Testing
- Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Obesity
Portion Control Treatment for Obesity
To date, no studies have been published assessing the effectiveness of portion control interventions in a primary care setting. The investigators will conduct a pilot study to assess the effectiveness of an intervention including…
- Trial name
- NCT01451554
- Testing
- portion control plate, Usual Care
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance
Using Mirabegron to Increase BP in Patients With POTS
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and…
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
- Trial name
- RAISE-BP (NCT06133075)
- Testing
- Mirabegron 50 MG, Mirabegron 25 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Homeless Persons, Primary Health Care
Aligning Resources to Care for Homeless Veterans
"Aligning Resources to Care for Homeless Veterans" (ARCH) will study ways to best organize and deliver primary care for homeless Veterans.
- Trial name
- ARCH (NCT01550757)
- Testing
- Embedded Peer Mentor
- Where
- 2 sites in United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Focal Segmental Glomerulosclerosis
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental…
- Trial name
- FONTII (NCT00814255)
- Testing
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Where
- 18 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.